42 related articles for article (PubMed ID: 23711070)
1. Serum levels of high mobility group box 1 correlate with disease severity in recessive dystrophic epidermolysis bullosa.
Petrof G; Abdul-Wahab A; Proudfoot L; Pramanik R; Mellerio JE; McGrath JA
Exp Dermatol; 2013 Jun; 22(6):433-5. PubMed ID: 23711070
[TBL] [Abstract][Full Text] [Related]
2. Mechanism underlying pruritus in recessive dystrophic epidermolysis bullosa: Role of interleukin-31 from mast cells and macrophages.
Lee SG; Kim SE; Jeong IH; Lee SE
J Eur Acad Dermatol Venereol; 2024 May; 38(5):895-903. PubMed ID: 38084871
[TBL] [Abstract][Full Text] [Related]
3. Epithelial HMGB1 Delays Skin Wound Healing and Drives Tumor Initiation by Priming Neutrophils for NET Formation.
Hoste E; Maueröder C; van Hove L; Catrysse L; Vikkula HK; Sze M; Maes B; Karjosukarso D; Martens L; Gonçalves A; Parthoens E; Roelandt R; Declercq W; Fuentes I; Palisson F; Gonzalez S; Salas-Alanis JC; Boon L; Huebener P; Mulder KW; Ravichandran K; Saeys Y; Schwabe RF; van Loo G
Cell Rep; 2019 Nov; 29(9):2689-2701.e4. PubMed ID: 31775038
[TBL] [Abstract][Full Text] [Related]
4. Potential of Systemic Allogeneic Mesenchymal Stromal Cell Therapy for Children with Recessive Dystrophic Epidermolysis Bullosa.
Petrof G; Lwin SM; Martinez-Queipo M; Abdul-Wahab A; Tso S; Mellerio JE; Slaper-Cortenbach I; Boelens JJ; Tolar J; Veys P; Ofuya M; Peacock JL; Martinez AE; McGrath JA
J Invest Dermatol; 2015 Sep; 135(9):2319-2321. PubMed ID: 25905587
[No Abstract] [Full Text] [Related]
5. Fibrosis as a Risk Factor for Cutaneous Squamous Cell Carcinoma in Recessive Dystrophic Epidermolysis Bullosa: A Systematic Review.
de Azevedo BLR; Roni GM; Torrelio RMF; da Gama-de-Souza LN
J Pediatr Genet; 2023 Jun; 12(2):97-104. PubMed ID: 37090823
[TBL] [Abstract][Full Text] [Related]
6. Extracellular matrix stiffness-The central cue for skin fibrosis.
Wang K; Wen D; Xu X; Zhao R; Jiang F; Yuan S; Zhang Y; Gao Y; Li Q
Front Mol Biosci; 2023; 10():1132353. PubMed ID: 36968277
[TBL] [Abstract][Full Text] [Related]
7. Immune Disregulation in Cutaneous Squamous Cell Carcinoma of Patients with Recessive Dystrophic Epidermolysis Bullosa: A Single Pilot Study.
Filoni A; Cicco G; Cazzato G; Bosco A; Lospalluti L; Tucci M; Cimmino A; Foti C; Marzullo A; Bonamonte D
Life (Basel); 2022 Jan; 12(2):. PubMed ID: 35207500
[TBL] [Abstract][Full Text] [Related]
8. Clinical trial of ABCB5+ mesenchymal stem cells for recessive dystrophic epidermolysis bullosa.
Kiritsi D; Dieter K; Niebergall-Roth E; Fluhr S; Daniele C; Esterlechner J; Sadeghi S; Ballikaya S; Erdinger L; Schauer F; Gewert S; Laimer M; Bauer JW; Hovnanian A; Zambruno G; El Hachem M; Bourrat E; Papanikolaou M; Petrof G; Kitzmüller S; Ebens CL; Frank MH; Frank NY; Ganss C; Martinez AE; McGrath JA; Tolar J; Kluth MA
JCI Insight; 2021 Nov; 6(22):. PubMed ID: 34665781
[TBL] [Abstract][Full Text] [Related]
9. A Review of Acquired Autoimmune Blistering Diseases in Inherited Epidermolysis Bullosa: Implications for the Future of Gene Therapy.
Patel PM; Jones VA; Behnam CT; Di Zenzo G; Amber KT
Antibodies (Basel); 2021 May; 10(2):. PubMed ID: 34067512
[TBL] [Abstract][Full Text] [Related]
10. Intravenous allogeneic umbilical cord blood-derived mesenchymal stem cell therapy in recessive dystrophic epidermolysis bullosa patients.
Lee SE; Lee SJ; Kim SE; Kim K; Cho B; Roh K; Kim SC
JCI Insight; 2021 Jan; 6(2):. PubMed ID: 33491668
[TBL] [Abstract][Full Text] [Related]
11. Immune tolerance of allogeneic haematopoietic cell transplantation supports donor epidermal grafting of recessive dystrophic epidermolysis bullosa chronic wounds.
Ebens CL; McGrath JA; Riedl JA; Keith AR; Lilja G; Rusch S; Keene DR; Tufa SF; Riddle MJ; Shanley R; Van Heest AE; Tolar J
Br J Dermatol; 2021 Jun; 184(6):1161-1169. PubMed ID: 32866988
[TBL] [Abstract][Full Text] [Related]
12. Cutaneous expression of TREM, vitamin D receptor and HMGB1 in vitamin D deficiency.
Nguyen AH; Lim VM; Fleegel JP; Hunter WJ; Agrawal DK
Int J Clin Exp Pathol; 2016 Aug; 9(8):8506-8512. PubMed ID: 32699567
[TBL] [Abstract][Full Text] [Related]
13. Leading edge: emerging drug, cell, and gene therapies for junctional epidermolysis bullosa.
Keith AR; Twaroski K; Ebens CL; Tolar J
Expert Opin Biol Ther; 2020 Aug; 20(8):911-923. PubMed ID: 32178539
[TBL] [Abstract][Full Text] [Related]
14. Epidermolysis Bullosa-Associated Squamous Cell Carcinoma: From Pathogenesis to Therapeutic Perspectives.
Condorelli AG; Dellambra E; Logli E; Zambruno G; Castiglia D
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31739489
[TBL] [Abstract][Full Text] [Related]
15. A multitask clustering approach for single-cell RNA-seq analysis in Recessive Dystrophic Epidermolysis Bullosa.
Zhang H; Lee CAA; Li Z; Garbe JR; Eide CR; Petegrosso R; Kuang R; Tolar J
PLoS Comput Biol; 2018 Apr; 14(4):e1006053. PubMed ID: 29630593
[TBL] [Abstract][Full Text] [Related]
16. Down-Regulation of Serum High-Mobility Group Box 1 Protein in Patients with Pulmonary Tuberculosis and Nontuberculous Mycobacterial Lung Disease.
Kim SY; Koh WJ; Park HY; Jeon K; Lee SY; Yim JJ; Shin SJ
Tuberc Respir Dis (Seoul); 2017 Apr; 80(2):153-158. PubMed ID: 28416955
[TBL] [Abstract][Full Text] [Related]
17. A living band-aid for epidermolysis bullosa.
Tolar J; Tolar M
Blood Transfus; 2015 Jan; 13(1):1-2. PubMed ID: 25636127
[No Abstract] [Full Text] [Related]
18. Innate sensing of microbial products promotes wound-induced skin cancer.
Hoste E; Arwert EN; Lal R; South AP; Salas-Alanis JC; Murrell DF; Donati G; Watt FM
Nat Commun; 2015 Jan; 6():5932. PubMed ID: 25575023
[TBL] [Abstract][Full Text] [Related]
19. HMGB1 in health and disease.
Kang R; Chen R; Zhang Q; Hou W; Wu S; Cao L; Huang J; Yu Y; Fan XG; Yan Z; Sun X; Wang H; Wang Q; Tsung A; Billiar TR; Zeh HJ; Lotze MT; Tang D
Mol Aspects Med; 2014 Dec; 40():1-116. PubMed ID: 25010388
[TBL] [Abstract][Full Text] [Related]
20. Advances in understanding and treating dystrophic epidermolysis bullosa.
Vanden Oever MJ; Tolar J
F1000Prime Rep; 2014; 6():35. PubMed ID: 24860657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
